{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:36:44Z","timestamp":1791419804978,"version":"4.3.3"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Nail lichen planus (NLP) is a chronic inflammatory disease of unknown etiology and has been recognized as a nail potentially critical disorder, which can be severe and rapidly worsen with irreversible scarring. Currently, the treatment options are limited based on disease progression. High-potency topical or intralesional corticosteroids are commonly considered first-line therapeutic options; however, these therapies are unsuitable for all patients with NLP, especially those with extensive lesions. As a potential therapeutic target for inflammatory skin diseases, Janus kinase (JAK) inhibitors can suppress both type-1 and type-2 cytokines, thereby reducing the immune response and resultant inflammation. Recent studies have suggested benefit in cutaneous lichen planus and lichen planopilaris with oral JAK inhibitors. Here, we report a case of severe NLP that exhibited a favorable response to tofacitinib treatment. A 41-year-old woman presented to our clinic with a 2-year history of nail dystrophy of all fingers of both hands. The NLP was finally confirmed by histopathology and the above clinical features. After the informed consent signature, tofacitinib monotherapy, 5\u2009mg twice a day, was then begun, and after 6\u2009months, the appearance of her nails had a significant improvement.<\/jats:p>","DOI":"10.3389\/fmed.2023.1301123","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:09:24Z","timestamp":1700158164000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Successful treatment of nail lichen planus with tofacitinib: a case report and review of the literature"],"prefix":"10.3389","volume":"10","author":[{"given":"Jundong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.annder.2022.01.010","article-title":"Nail lichen planus: a review of clinical presentation, diagnosis and therapy","volume":"149","author":"Grover","year":"2022","journal-title":"Ann Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1080\/09546634.2018.1546043","article-title":"JAK-inhibitors in dermatology: current evidence and future applications","volume":"30","author":"Ciechanowicz","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.det.2020.12.002","article-title":"Review of nail lichen planus: epidemiology, pathogenesis, diagnosis, and treatment","volume":"39","author":"Gupta","year":"2021","journal-title":"Dermatol Clin"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.jaad.2020.02.056","article-title":"Isolated nail lichen planus: an expert consensus on treatment of the classical form","volume":"83","author":"Iorizzo","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jaad.2018.02.010","article-title":"Lichen planus and lichenoid dermatoses: clinical overview and molecular basis","volume":"79","author":"Tziotzios","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1080\/09546634.2022.2116926","article-title":"JAK inhibitors in lichen planus: a review of pathogenesis and treatments","volume":"33","author":"Motamed-Sanaye","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.jaad.2020.05.104","article-title":"Tofacitinib in the treatment of lichen planopilaris: a retrospective review","volume":"83","author":"Plante","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.2174\/1874467210666170113104503","article-title":"Tofacitinib, an Oral Janus kinase inhibitor: perspectives in dermatology","volume":"24","author":"Kostovic","year":"2017","journal-title":"Curr Med Chem"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ddg.14668_g","article-title":"JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety","volume":"23","author":"Elmariah","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jdv.19426","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","author":"Yoon","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e2320351","DOI":"10.1001\/jamanetworkopen.2023.20351","article-title":"Janus kinase inhibitors for alopecia Areata: a systematic review and meta-analysis","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1195858","DOI":"10.3389\/fimmu.2023.1195858","article-title":"The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients","volume":"14","author":"Mao","year":"2023","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamadermatol.2021.5082","article-title":"Treatment of severe nail lichen planus with Baricitinib","volume":"158","author":"Punchera","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1001\/jamadermatol.2020.4555","article-title":"Tofacitinib as treatment for nail lichen planus associated with alopecia Universalis","volume":"157","author":"Iorizzo","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamadermatol.2020.3095","article-title":"Tofacitinib for the treatment of nail lesions and palmoplantar Pustulosis in synovitis, acne, Pustulosis, hyperostosis, and osteitis syndrome","volume":"157","author":"Li","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000524246","article-title":"Mycophenolate Mofetil in the treatment of severe corticosteroid-dependent or corticosteroid-resistant nail lichen planus: a case series of 5 patients","volume":"8","author":"Duplaine","year":"2022","journal-title":"Skin Appendage Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000523796","article-title":"Successful treatment of nail lichen planus with a lacquer containing urea, keratinase, and a retinoid molecule: report of 10 cases","volume":"14","author":"Milani","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4103\/JCAS.JCAS_156_20","article-title":"Intra-individual right-left comparative study of combined therapy of Intramatricial triamcinolone and platelet-Rich plasma vs. Intramatricial triamcinolone only in lichen planus-associated nail dystrophy","volume":"14","author":"Rehman","year":"2021","journal-title":"J Cutan Aesthet Surg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/phpp.12528","article-title":"Treatment of nail lichen planus with localized bath-PUVA","volume":"36","author":"da Veiga","year":"2020","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/ddg.12325","article-title":"Successful treatment of palmoplantar nail lichen planus with cyclosporine","volume":"12","author":"Florian","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2340\/00015555-0814","article-title":"Successful treatment of nail lichen planus with topical tacrolimus","volume":"90","author":"Ujiie","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000321419","article-title":"Nail lichen planus: successful treatment with Etanercept","volume":"2","author":"Irla","year":"2010","journal-title":"Case Rep Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0190-9622(89)80060-X","article-title":"Lichen planus of the nail: treatment with antimalarials","volume":"20","author":"Mostafa","year":"1989","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1301123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:09:25Z","timestamp":1700158165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1301123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":28,"alternative-id":["10.3389\/fmed.2023.1301123"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1301123","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"article-number":"1301123"}}